Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Activation of T cells to the capsid of adeno-associated virus (AAV) serotype 2 vectors has been implicated in liver toxicity in a recent human gene therapy trial of hemophilia B. To further investigate this kind of toxicity, we evaluated T-cell responses to AAV capsids after intramuscular injection of vectors into mice and nonhuman primates. High levels of T cells specific to capsids of vectors based on AAV2 and a phylogenetically related AAV variant were detected. Vectors from other AAV clades such as AAV8 (ref. 3), however, did not lead to activation of capsid-specific T cells. Through the generation of AAV2-AAV8 hybrids and the creation of site-directed mutations, we mapped the domain that directs the activation of T cells to the RXXR motif on VP3, which was previously shown to confer binding of the virion to heparan sulfate proteoglycan (HSPG). Evaluation of natural and engineered AAV variants showed direct correlations between heparin binding, uptake into human dendritic cells (DCs) and activation of capsid-specific T cells. The role of heparin binding in the activation of CD8(+) T cells may be useful in modulating the immunogenicity of antigens and improving the safety profile of existing AAV vectors for gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the VP3 VIII variable region of AAV8 is not involved in HSPG recognition by the cell surface receptor57.”
From An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species (2024) · cites this paper as [57]
In the citing paper
“However, this does not apply here because AAV8 does not elicit a CD8+ T cell response against capsid in mice and because the vector dose was anyhow too low to generate such a response.25,66,67”
From TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling (2024) · cites this paper as [66]
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 1×
“dtd" [ ]> Activation of T cells to the capsid of adeno-associated virus (AAV) serotype 2 vectors has been implicated in liver toxicity in a recent human gene therapy trial of hemophilia”
BackgroundNovel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Self-citationSummerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406 · cited 1×
“Through the generation of AAV2-AAV8 hybrids and the creation of site-directed mutations, we mapped the domain that directs the activation of T cells to the RXXR motif on VP3, which was previously shown to confer binding of the virion to heparan sulfate proteoglycan (HSPG”
BackgroundClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
Self-citationThe atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., & Chapman, M. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162250899 · Cited by 612 · cited 1×
“The VP3 protein comprises the structural backbone for the particle architecture as well as the majority of variable domains between AAV2 and AAV8 (refs”
BackgroundIdentification of a heparin-binding motif on adeno-associated virus type 2 capsids
Kern, A., Schmidt, K., Leder, C., Müller, O. J., Wobus, C. E., Bettinger, K., Von der Lieth, C. W., King, J. A., & Kleinschmidt, J. A. (2003) · Journal of Virology · doi:10.1128/jvi.77.20.11072-11081.2003 · Cited by 380 · cited 1×
“Through the generation of AAV2-AAV8 hybrids and the creation of site-directed mutations, we mapped the domain that directs the activation of T cells to the RXXR motif on VP3, which was previously shown to confer binding of the virion to heparan sulfate proteoglycan (HSPG”
BackgroundOpie, S. R., Warrington, Agbandje-McKenna, M., Zolotukhin, S., & Muzyczka, N. (2003) · Journal of Virology · doi:10.1128/jvi.77.12.6995-7006.2003 · Cited by 364 · cited 1×
“Through the generation of AAV2-AAV8 hybrids and the creation of site-directed mutations, we mapped the domain that directs the activation of T cells to the RXXR motif on VP3, which was previously shown to confer binding of the virion to heparan sulfate proteoglycan (HSPG”
BackgroundAdeno-associated viruses undergo substantial evolution in primates during natural infections
Gao, G., Alvira, M. R., Somanathan, S., Lu, Y., Vandenberghe, L. H., Rux, J. J., Calcedo, R., Sanmiguel, J., Abbas, Z., & Wilson, J. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0937739100 · Cited by 323
Self-citationHalbert, C. L., Allen, J. M., & Miller, A. D. (2001) · Journal of Virology · doi:10.1128/jvi.75.14.6615-6624.2001 · Cited by 314 · cited 1×
“All members of AAVs from Clades A, C, D, E and F are missing the RXXR motif, and those that have been studied do not bind heparin with the avidity of AAV2 (ref”
BackgroundWilson, N. S., & Villadangos, J. A. (2005) · Advances in Immunology · doi:10.1016/s0065-2776(04)86007-3 · Cited by 176 · cited 1×
“Pathways by which this occurs begin with endocytotic or phagocytotic uptake followed by a series of proteolytic steps and eventual loading of peptides onto MHC class I complexe”
Background
Cited by
Viral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404
Self-citationImmune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“81 83-88 However, if the observed toxicity was indeed related to the catabolism of the capsid, then this aspect of drug metabolism needed to be understood in greater detail.”
Gene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926
“it was discovered that the AAV-2 capsid heparin binding motif was responsible for T-cell activation (65).”
BackgroundTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Jessup, M., Greenberg, B., Mancini, D., Cappola, T., Pauly, D. F., Jaski, B., Yaroshinsky, A., Zsebo, K. M., Dittrich, H., & Hajjar, R. J. (2011) · Circulation · doi:10.1161/circulationaha.111.022889 · Cited by 760
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Grimm, D., Lee, J. S., Wang, L., Desai, T., Akache, B., Storm, T. A., & Kay, M. A. (2008) · Journal of Virology · doi:10.1128/jvi.00254-08 · Cited by 696
Self-citationAntibody-based protection against HIV infection by vectored immunoprophylaxis
Balazs, A. B., Chen, J., Hong, C. M., Rao, D. S., Yang, L., & Baltimore, D. (2012) · Nature · doi:10.1038/nature10660 · Cited by 545
“Studies in non-human primates have shown that the elicitation of capsid-specific cytotoxic T-lymphocytes is limited to AAV capsids that exhibit heparin-binding activit”
BackgroundPhase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector
Bowles, D. E., McPhee, S. W., Li, C., Gray, S. J., Samulski, J. J., Camp, A. S., Li, J., Wang, B., Monahan, P. E., Rabinowitz, J. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.237 · Cited by 400
AAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
Gene Therapy Leaves a Vicious Cycle
Goswami, R., Subramanian, G., Silayeva, L., Newkirk, I., Doctor, D., Chawla, K., Chattopadhyay, S., Chandra, D., Chilukuri, N., & Betapudi, V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00297 · Cited by 347
“Adding empty vectors of AAV to the final vector preparations to serve as a decoy and developing new vectors with high transduction and gene expression potential as well as better understanding of Tcell response to all AAV serotypes in clinical settings would reduce inflammation, immune response, and other viral partic…”
Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents
Calcedo, R., Morizono, H., Wang, L., McCarter, R., He, J., Jones, D., Batshaw, M. L., & Wilson, J. M. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05107-11 · Cited by 345
“The discovery of new serotypes, including AAV8 (6), has provided alternative vectors with substantial advantages over AAV2 in terms of gene transfer efficiency (4, 11, 13, 18), lower prevalence of neutralizing antibodies (NAbs) in the human population (1, 3), and less propensity to activate T cells for capsid proteins…”
BackgroundSelf-citationNathwani, A. C., Rosales, C., McIntosh, J., Rastegarlari, G., Nathwani, D., Raj, D., Nawathe, S., Waddington, S. N., Bronson, R., Jackson, S., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.274 · Cited by 345
Zhu, J., Huang, X., & Yang, Y. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37607 · Cited by 330
In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector
Zinn, E., Pacouret, S., Khaychuk, V., Turunen, H. T., Carvalho, L. S., Andres-Mateos, E., Shah, S., Shelke, R., Maurer, A. C., Plovie, E., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.019 · Cited by 310
“…et al., 2002; Grieger et al., 2006), a limited number of docking sites for monoclonal antibodies (DiMattia et al., 2012), a motif enhancing T-cell immunogenicity (Vandenberghe et al., 2006), and a select number MHCI restricted T-cell epitopes (Mingozzi et al., 2007) have previously been mapped..”
BackgroundSelf-citationComparative Analysis of Adeno-Associated Viral Vector Serotypes 1, 2, 5, 7, And 8 in Mouse Brain
Taymans, J.-M., Vandenberghe, L. H., Haute, C. V. D., Thiry, I., Deroose, C. M., Mortelmans, L., Wilson, J. M., Debyser, Z., & Baekelandt, V. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.178 · Cited by 305
“In addition, the use of alternative serotypes might overcome the cellular immune response to the AAV2 capsid as this was implicated in vector toxicity in a human gene therapy trial (Manno et al., 2006; Vandenberghe et al., 2006).”
Self-citationMingozzi, F., Meulenberg, J. J., Hui, D. J., Basner-Tschakarjan, E., Hasbrouck, N. C., Edmonson, S. A., Hutnick, N. A., Betts, M. R., Kastelein, J. J., Stroes, E. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-167510 · Cited by 295
Viral vectors for gene delivery to the central nervous system
Lentz, T. B., Gray, S. J., & Samulski, R. J. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.09.014 · Cited by 271
Mingozzi, F., Hasbrouck, N. C., Basner-Tschakarjan, E., Edmonson, S. A., Hui, D. J., Sabatino, D. E., Zhou, S., Wright, J. F., Jiang, H., Pierce, G. F., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080093 · Cited by 254
Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors
Allocca, M., Mussolino, C., Garcia-Hoyos, M., Sanges, D., Iodice, C., Petrillo, M., Vandenberghe, L. H., Wilson, J. M., Marigo, V., Surace, E. M., et al. (2007) · Journal of Virology · doi:10.1128/jvi.01327-07 · Cited by 246
“29R (55), and AAV2/5 (11) vectors harboring the AAV2 vector genome, coding for EGFP, under the control of the ubiquitous CMV promoter.”
BackgroundSelf-citationMartino, A. T., Suzuki, M., Markusic, D. M., Zolotukhin, I., Ryals, R. C., Moghimi, B., Ertl, H. C. J., Muruve, D. A., Lee, B., & Herzog, R. W. (2011) · Blood · doi:10.1182/blood-2010-10-314518 · Cited by 246
Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey
Vandenberghe, L. H., Bell, P., Maguire, A. M., Cearley, C. N., Xiao, R., Calcedo, R., Wang, L., Castle, M. J., Maguire, A. C., Grant, R., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002103 · Cited by 242
Self-citationBucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Immune Responses to AAV in Clinical Trials
Mingozzi, F., & High, K. (2007) · Current Gene Therapy · doi:10.2174/156652307782151425 · Cited by 238
“Another hypothesis proposes that a specific motif (heparin binding domain) within the dominant protein of the AAV-2 capsid favors receptor-mediated uptake of vector by human dendritic cells, with activation of capsid-specific CD8+ T cells occurring on that basis [ Vandenberghe et al., 2006 ].”
BackgroundVandendriessche, T., Thorrez, L., Acosta‐Sanchez, A., Petrus, I., Wang, L., Ma, L., De Waele, L., Iwasaki, Y., Gillijns, V., Wilson, J. M., et al. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02220.x · Cited by 209
Self-citationNovel AAV serotypes for improved ocular gene transfer
Lebherz, C., Maguire, A., Tang, W., Bennett, J., & Wilson, J. M. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1126 · Cited by 208
“There is, therefore, less possibility that delivery of these vectors to the human eye will result in immune-mediated clearance (unlike the situation for AAV2/2 [42]).”
BackgroundSelf-citationMingozzi, F., & High, K. A. (2017) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041936 · Cited by 206
Adeno-Associated Virus Vectorology, Manufacturing, and Clinical Applications
Grieger, J. C., & Samulski, R. J. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-386509-0.00012-0 · Cited by 199
“, 2007), and AAV8 was shown to have reduced heparin binding, which reduced cytotoxic capsid-specific T cell activation (Vandenberghe et al., 2006).”
BackgroundRecent developments in adeno‐associated virus vector technology
Büning, H., Perabo, L., Coutelle, O., Quadt‐Humme, S., & Hallek, M. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1205 · Cited by 187
“This activation pathway has also been described following AAV vector application [167–169].”
BackgroundMethodExpanded Repertoire of AAV Vector Serotypes Mediate Unique Patterns of Transduction in Mouse Brain
Cearley, C. N., Vandenberghe, L. H., Parente, M. K., Carnish, E. R., Wilson, J. M., & Wolfe, J. H. (2008) · Molecular Therapy · doi:10.1038/mt.2008.166 · Cited by 182
Self-citationLimberis, M. P., Vandenberghe, L. H., Zhang, L., Pickles, R. J., & Wilson, J. M. (2009) · Molecular Therapy · doi:10.1038/mt.2008.261 · Cited by 184
Self-citationImmunity to adeno-associated virus vectors in animals and humans: a continued challenge
Zaiss, A. K., & Muruve, D. A. (2008) · Gene Therapy · doi:10.1038/gt.2008.54 · Cited by 180
Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174
Qiao, C., Yuan, Z., Li, J., He, B., Zheng, H., Mayer, C., Li, J., & Xiao, X. (2011) · Gene Therapy · doi:10.1038/gt.2010.157 · Cited by 163
Martino, A. T., Basner-Tschakarjan, E., Markusic, D. M., Finn, J. D., Hinderer, C., Zhou, S., Ostrov, D. A., Srivastava, A., Ertl, H. C. J., Terhorst, C., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460733 · Cited by 162
“Earlier preclinical studies suggested that MHC I presentation of capsid antigen could be avoided by use of capsids lacking heparin-binding sites such as AAV8.(28) However, T-cell responses and loss of hF.”
BackgroundKornegay, J. N., Li, J., Bogan, J. R., Bogan, D. J., Chen, C., Zheng, H., Wang, B., Qiao, C., Howard, J. F., & Xiao, X. (2010) · Molecular Therapy · doi:10.1038/mt.2010.94 · Cited by 158
Self-citationTailoring the AAV vector capsid for gene therapy
Vandenberghe, L. H., Wilson, J. M., & Gao, G. (2009) · Gene Therapy · doi:10.1038/gt.2008.170 · Cited by 155
Self-citationLimberis, M. P., & Wilson, J. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601433103 · Cited by 155
Self-citationAllay, J. A., Sleep, S., Long, S., Tillman, D. M., Clark, R., Carney, G., Fagone, P., McIntosh, J. H., Nienhuis, A. W., Davidoff, A. M., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.202 · Cited by 152
“Clearance of AAV8 from the systemic circulation in macaques was also significantly quicker than with other serotypes (Nathwani et al., 2007), and AAV8 was shown to have reduced heparin binding, which reduced cytotoxic capsid-specific T cell activation (Vandenberghe et al., 2006).”
BackgroundVandenberghe, L. H., Xiao, R., Lock, M., Lin, J., Korn, M., & Wilson, J. M. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.107 · Cited by 151
“AAT levels were determined from serum samples by AATspecific enzyme-linked immunosorbent assay (Vandenberghe et al., 2006).”
InfluentialSelf-citationDurability of transgene expression after rAAV gene therapy
Muhuri, M., Lévy, D., Schulz, M., McCarty, D. M., & Gao, G. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.03.004 · Cited by 172
Self-citationSystematic Evaluation of AAV Vectors for Liver directed Gene Transfer in Murine Models
Wang, L., Wang, H., Bell, P., McCarter, R. J., He, J., Calcedo, R., Vandenberghe, L. H., Morizono, H., Batshaw, M. L., & Wilson, J. M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.246 · Cited by 139
Self-citationAdeno-Associated Viral Vectors and Their Redirection to Cell-Type Specific Receptors
Michelfelder, S., & Trepel, M. (2009) · Advances in genetics · doi:10.1016/s0065-2660(09)67002-4 · Cited by 149
The Pleiotropic Effects of Natural AAV Infections on Liver-directed Gene Transfer in Macaques
Wang, L., Calcedo, R., Wang, H., Bell, P., Grant, R., Vandenberghe, L. H., Sanmiguel, J., Morizono, H., Batshaw, M. L., & Wilson, J. M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.245 · Cited by 130
Self-citationGPR108 Is a Highly Conserved AAV Entry Factor
Dudek, A. M., Zabaleta, N., Zinn, E., Pillay, S., Zengel, J., Porter, C., Franceschini, J. S., Estelien, R., Carette, J. E., Zhou, G. L., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.005 · Cited by 132
Self-citationSaunders, K. O., Wang, L., Joyce, M. G., Yang, Z.-Y., Balazs, A. B., Cheng, C., Ko, S.-Y., Kong, W.-P., Rudicell, R. S., Georgiev, I. S., et al. (2015) · Journal of Virology · doi:10.1128/jvi.00908-15 · Cited by 122
“Although AAV8-vectored gene transfer has been proposed to reduce the immunogenicity of the transgene (32), human proteins such as factor IX elicit a humoral response in macaques when delivered by AAV8 vectors (33).”
BackgroundSelf-citationHepatic Gene Transfer as a Means of Tolerance Induction to Transgene Products
LoDuca, P., Hoffman, B., & Herzog, R. (2009) · Current Gene Therapy · doi:10.2174/156652309787909490 · Cited by 114
Wang, L., Figueredo, J., Calcedo, R., Lin, J., & Wilson, J. M. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.001 · Cited by 113
Self-citationHareendran, S., Balakrishnan, B., Sen, D., Kumar, S., Srivastava, A., & Jayandharan, G. R. (2013) · Reviews in Medical Virology · doi:10.1002/rmv.1762 · Cited by 113
“(2) If AAV is captured by antigen-cell receptor (TCR) of CD4+ Tcells [53].”
BackgroundInfluentialThe Role of the Adeno-Associated Virus Capsid in Gene Transfer
Van Vliet, K. M., Blouin, V., Brument, N., Agbandje-McKenna, M., & Snyder, R. O. (2008) · Methods in Molecular Biology™ · doi:10.1007/978-1-59745-210-6_2 · Cited by 116
“This region was identified as being involved in uptake into dendritic cells, as well as the activation of capsid-specific T cells [94] .”
BackgroundPre-existing AAV Capsid-specific CD8+ T Cells are Unable to Eliminate AAV-transduced Hepatocytes
Li, H., Murphy, S. L., Giles-Davis, W., Edmonson, S., Xiang, Z., Li, Y., Lasaro, M. O., High, K. A., & Ertl, H. C. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300090 · Cited by 108
Targeting the heart with gene therapy-optimized gene delivery methods
Müller, O. J., Katus, H. A., & Bekeredjian, R. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.09.021 · Cited by 108
“Interestingly, deletion of heparin binding reduced uptake in human dendritic cells and activation of capsid-specific Tcells [ 110 ].”
Gao, G., Wang, Q., Calcedo, R., Mays, L., Bell, P., Wang, L., Vandenberghe, L. H., Grant, R., Sanmiguel, J., Furth, E. E., et al. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.060 · Cited by 103
“…to primates, including AAV serotypes 7 and 8, which have low sero-prevalence in humans, diminished activation of capsid T cells, and improved transduction efficiency of hepatocytes in most preclinical models (Gao et al. , 2002; Vandenberghe et al. , 2006; Wang et al. , 2007; Calcedo et al. , 2009).”
Self-citationSystemic delivery of adeno-associated viral vectors
Duan, D. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.07.006 · Cited by 103
AAV8-mediated Hepatic Gene Transfer in Infant Rhesus Monkeys (Macaca mulatta)
Wang, L., Bell, P., Lin, J., Calcedo, R., Tarantal, A. F., & Wilson, J. M. (2011) · Molecular Therapy · doi:10.1038/mt.2011.151 · Cited by 102
Self-citationToromanoff, A., Chérel, Y., Guilbaud, M., Penaud-Budloo, M., Snyder, R. O., Haskins, M. E., Deschamps, J.-Y., Guigand, L., Podevin, G., Arruda, V. R., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.87 · Cited by 99
Mays, L. E., Vandenberghe, L. H., Xiao, R., Bell, P. L., Nam, H.-J., Agbandje‐McKenna, M., & Wilson, J. M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803965 · Cited by 109
“nLacZ elicits virtually no immune response to either nLacZ or the capsid, consistent with previous reports of aberrant T cell responses in mice (40, 41, 43).”
ResultSelf-citationImmune Response Mechanisms against AAV Vectors in Animal Models
Martino, A. T., & Markusic, D. M. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.12.008 · Cited by 97
AAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success
M. Mitchell, A., C. Nicolson, S., K. Warischalk, J., & Jude Samulski, R. (2010) · Current Gene Therapy · doi:10.2174/156652310793180706 · Cited by 96
Murphy, S. L., & High, K. A. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06942.x · Cited by 109
“Finally it has been proposed that there will be differences in capsid processing and presentation with alternate AAV serotypes, because of different kinetics of uncoating, differences in intracellular trafficking, or differences in antigen processing (Vandenberghe et al, 2006).”
BackgroundErtl, H. C. J., & High, K. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.172 · Cited by 94
“67 A subsequent clinical trial with a rAAV8 vector disproved this concept, 60 since four out of six subjects infused with the highest vector dose developed transaminase elevation, increases in AAV8 capsid-specific circulating T cells, and a drop in FIX levels.”
AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects
Hasbrouck, N. C., & High, K. A. (2008) · Gene Therapy · doi:10.1038/gt.2008.71 · Cited by 100
Ohshima, S., Shin, J.-H., Yuasa, K., Nishiyama, A., Kira, J., Okada, T., & Takeda, S. (2009) · Molecular Therapy · doi:10.1038/mt.2008.225 · Cited by 92
High-efficiency purification of divergent AAV serotypes using AAVX affinity chromatography
Florea, M., Nicolaou, F., Pacouret, S., Zinn, E. M., Sanmiguel, J. C., Andrés‐Mateos, E., Unzu, C., Wagers, A. J., & Vandenberghe, L. H. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.12.009 · Cited by 98
Self-citationImproved Induction of Immune Tolerance to Factor IX by Hepatic AAV-8 Gene Transfer
Cooper, M., Nayak, S., Hoffman, B. E., Terhorst, C., Cao, O., & Herzog, R. W. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.161 · Cited by 90
Advancements in mRNA Encoded Antibodies for Passive Immunotherapy
Deal, C. E., Carfí, A., & Plante, O. J. (2021) · Vaccines · doi:10.3390/vaccines9020108 · Cited by 91
Gene therapy for haemophilia: a long and winding road
High, K. A. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04369.x · Cited by 86
Grimstein, C., Choi, Y., Wasserfall, C. H., Satoh, M., Atkinson, M. A., Brantly, M., Campbell‐Thompson, M., & Song, S. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-21 · Cited by 86
“AAV serotype 8 vector is unique for this purpose because it can mediate long term and high levels of transgene expression in the liver and muscle, but is not able to transduce dendritic cells and has low immunogenicity [48,49].”
BackgroundRoyo, N. C., Vandenberghe, L. H., Ma, J.-Y., Hauspurg, A. K., Yu, L., Maronski, M., Johnston, J., Dichter, M. A., Wilson, J. M., & Watson, D. J. (2007) · Brain Research · doi:10.1016/j.brainres.2007.11.015 · Cited by 100
“AAVhu29R is a variant of AAV2 capsid with SGNT at the RXXR sequence that blocks heparin binding, in addition to five other single amino acid changes outside the RXXR region [30].”
BackgroundSelf-citationBoye, S. L., Bennett, A., Scalabrino, M. L., McCullough, K. T., Van Vliet, K., Choudhury, S., Ruan, Q., Peterson, J., Agbandje-McKenna, M., & Boye, S. E. (2016) · Journal of Virology · doi:10.1128/jvi.00200-16 · Cited by 79
“Previously, it was shown that the substitution of key canonical HS binding residues of AAV2 into AAV5 and AAV8 capsids conferred binding to HS (29, 51).”
BackgroundKassim, S. H., Li, H., Vandenberghe, L. H., Hinderer, C., Bell, P., Marchadier, D., Wilson, A., Cromley, D., Redon, V., Yu, H., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013424 · Cited by 79
“presentation of capsids [49,50].”
Self-citationDuchenne Muscular Dystrophy Gene Therapy in the Canine Model
Duan, D. (2015) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.006 · Cited by 88
Adeno-associated viral vectors for the treatment of hemophilia
High, K. A., & Anguela, X. M. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv475 · Cited by 82
“Among others, uptake by dendritic cells of the AAV2 virion in a process mediated by binding to heparan sulfate proteoglycans followed by the activation of capsid-specific T cells (20) or the presence of alternative open reading frames in the FIX coding sequence (21) were proposed as the culprits.”
BackgroundVandenberghe, L. H., Breous, E., Nam, H.-J., Gao, G., Xiao, R., Sandhu, A., Johnston, J., Debyser, Z., Agbandje‐McKenna, M., & Wilson, J. M. (2009) · Gene Therapy · doi:10.1038/gt.2009.101 · Cited by 81
Self-citationAdeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 79
AAV-ID: A Rapid and Robust Assay for Batch-to-Batch Consistency Evaluation of AAV Preparations
Pacouret, S., Bouzelha, M., Shelke, R., Andres-Mateos, E., Xiao, R., Maurer, A., Mevel, M., Turunen, H., Barungi, T., Penaud-Budloo, M., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.001 · Cited by 69
“virus uptake into human dendritic cells (DCs) and capsid-specific T cell activation.(31)”
BackgroundSelf-citationStrategies to Modulate Immune Responses: A New Frontier for Gene Therapy
Arruda, V. R., Favaro, P., & Finn, J. D. (2009) · Molecular Therapy · doi:10.1038/mt.2009.150 · Cited by 66
Homs, J., Ariza, L., Pagès, G., Udina, E., Navarro, X., Chillón, M., & Bosch, A. (2011) · Gene Therapy · doi:10.1038/gt.2011.7 · Cited by 69
Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors
Lu, Y., & Song, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909520106 · Cited by 69
“The work done by Vandenberghe and colleagues suggests that this is due to the inability of transduction of DCs (8).”
BackgroundLorain, S., Gross, D.-A., Goyenvalle, A., Danos, O., Davoust, J., & Garcia, L. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300377 · Cited by 62
Barker, S. E., Broderick, C. A., Robbie, S. J., Duran, Y., Natkunarajah, M., Buch, P., Balaggan, K. S., MacLaren, R. E., Bainbridge, J. W. B., Smith, A. J., et al. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1327 · Cited by 59
“Furthermore, AAV serotypes that do not express HSPG binding motifs appeared inherently less immunogenic [43].”
BackgroundBrown, D., Altermatt, M., Dobreva, T., Chen, S., Wang, A., Thomson, M., & Gradinaru, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.730825 · Cited by 60
“…has the potential to reduce activation of the immune system by detargeting cell types, such as dendritic cells, that have an increased ability to activate T-cells (Herzog et al., 2019; Rogers et al., 2017; Rossi et al., 2019; Somanathan et al., 2010; Vandenberghe et al., 2006; Zhu et al., 2009).”
BackgroundGene therapy for Duchenne muscular dystrophy
Ramos, J. N., & Chamberlain, J. S. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1088780 · Cited by 69
“AAV capsid and transgene-specific responses by effector CD8 cells has been reported in multiple animal models and in humans [37,38,79-86].”
BackgroundGene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment
Pierce, G. F., Lillicrap, D., Pipe, S. W., & VandenDriessche, T. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02410.x · Cited by 58
Dual Reporter Comparative Indexing of rAAV Pseudotyped Vectors in Chimpanzee Airway
Flotte, T. R., Fischer, A. C., Goetzmann, J., Mueller, C., Cebotaru, L., Yan, Z., Wang, L., Wilson, J. M., Guggino, W. B., & Engelhardt, J. F. (2010) · Molecular Therapy · doi:10.1038/mt.2009.230 · Cited by 57
Self-citationMorizono, K., Ku, A. T., Xie, Y., Harui, A., Kung, S. K. P., Roth, M. D., Lee, B., & Chen, I. S. Y. (2010) · Journal of Virology · doi:10.1128/jvi.00435-10 · Cited by 58
Immune Responses to AAV Capsid: Are Mice Not Humans After All?
Herzog, R. W. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300123 · Cited by 56
Immune barriers to successful gene therapy
Wu, T.-L., & Ertl, H. C. J. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.11.005 · Cited by 57
Wang, Z., Tapscott, S. J., Chamberlain, J. S., & Storb, R. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00201 · Cited by 53
“…to heparan sulfate proteoglycans (HSPG) was suggested to facilitate the uptake of certain AAV serotypes, such as AAV2, by dendritic cells (DC), which leads to antigen processing,MHC class I antigen presentation,and a consequent cell-mediated cytotoxic T cell responses (Vandenberghe et al., 2006).”
BackgroundIsolation and evaluation of novel adeno-associated virus sequences from porcine tissues
Bello, A., Tran, K., Chand, A., Doria, M., Allocca, M., Hildinger, M., Beniac, D. R., Kranendonk, C., Auricchio, A., & Kobinger, G. P. (2009) · Gene Therapy · doi:10.1038/gt.2009.82 · Cited by 58
Recent advances in gene therapy for lysosomal storage disorders
Amalfitano, A., & Rastall, D. P. W. (2015) · The Application of Clinical Genetics · doi:10.2147/tacg.s57682 · Cited by 60
Löw, K., Aebischer, P., & Schneider, B. L. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.174 · Cited by 50
“The immunogenicity of AAV seems to be determined by its capacity to bind heparan sulfate proteoglycan patches at the surface of dendritic cells (Vandenberghe et al. , 2006; Lu and Song, 2009).”
Sen, D., Gadkari, R. A., Sudha, G., Gabriel, N., Kumar, Y. S., Selot, R., Samuel, R., Rajalingam, S., Ramya, V., Nair, S. C., et al. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.195 · Cited by 51
“…and proteasomally processed AAV peptides are transported to the endoplasmic reticulum and are restricted by MHC Class I molecules (Yan et al., 2002; Vandenberghe et al., 2006; Finn Pooled serum samples from WT-AAV8 or S/K-AAV8 mutant injected mice (n = 4 per group) 4 weeks after vector…”
BackgroundRecent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia
Ajufo, E., & Cuchel, M. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0579-0 · Cited by 51
Le Guiner, C., Stieger, K., Toromanoff, A., Guilbaud, M., Mendes-Madeira, A., Devaux, M., Guigand, L., Cherel, Y., Moullier, P., Rolling, F., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102538 · Cited by 50
“The evaluation of other AAV serotypes could be interesting, such as serotype 8, which has already been demonstrated to be less immunogenic in the muscle [43,44,45].”
BackgroundChuah, M., Evens, H., & VandenDriessche, T. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12215 · Cited by 58
Bogner, B., Boye, S. L., Min, S.-H., Peterson, J. J., Ruan, Q., Zhang, Z., Reitsamer, H. A., Hauswirth, W. W., & Boye, S. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128759 · Cited by 48
Cabanes‐Creus, M., Westhaus, A., Navarro, R. G., Baltazar, G., Zhu, E., Amaya, A. K., Liao, S. H. Y., Scott, S., Sallard, E., Dilworth, K. L., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.004 · Cited by 45
Lai, C.-M., Estcourt, M. J., Wikstrom, M., Himbeck, R. P., Barnett, N. L., Brankov, M., Tee, L. B. G., Dunlop, S. A., Degli-Esposti, M. A., & Rakoczy, E. P. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3253 · Cited by 44
“A recent study found high levels of T cells specific to vector capsids based on rAAV2 and a related rAAV variant after intramuscular injection.(34) In addition, elicitation of immune responses due to delivery route,(28,32,33,35,36) or nature of transgene expressed, has been observed.”
BackgroundGene therapy strategies for hemophilia: benefits versus risks
Petrus, I., Chuah, M., & VandenDriessche, T. (2010) · The Journal of Gene Medicine · doi:10.1002/jgm.1500 · Cited by 50
“This could be of particular importance because it was suggested that the uptake of AAV2 into APCs, presumably mediated by heparan sulfate proteoglycan receptors, might direct CTL activation against the AAV2 capsids [186].”
Background
Metadata
- Authors
- Vandenberghe, L. H., Wang, L., Somanathan, S., Zhi, Y., Figueredo, J., Calcedo, R., Sanmiguel, J., Desai, R. A., Chen, C. S., Johnston, J., Grant, R. L., Gao, G., & Wilson, J. M.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Wilson, James M
- ORCID
- Venue
- Nature Medicine
- Published
- 2006-07-16
- Volume
- 12
- Issue
- 8
- Pages
- 967-971
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2080951809
- Cited by
- 208
- References
- 17
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 5 · 2023: 5 · 2022: 7 · 2021: 7 · 2020: 4 · 2019: 6 · 2018: 5 · 2017: 9 · 2016: 3 · 2015: 15 · 2014: 6 · 2013: 14 · 2012: 7
- FWCI
- 12.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- National Science Foundation
- GlaxoSmithKline
- National Heart, Lung, and Blood Institute (P01-HL-05407)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK047757)
- National Institute of Biomedical Imaging and Bioengineering
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- AAV2, AAV capsid, T cell activation, heparin binding, heparan sulfate proteoglycans, VP3, dendritic cell uptake, CD8+ T cells, AAV8, hepatotoxicity, hemophilia B, non-human primates
- MeSH terms
- Dependovirus, Animals, Capsid, Dendritic Cells, Genetic Markers, Genetic Vectors, Cricetinae, HeLa Cells, Heparin, Humans, Interferon-gamma, Kinetics, Leukocytes, Mononuclear, Lymphocyte Activation, Macaca fascicularis, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Serotyping, T-Lymphocytes, Time Factors, Interleukin-4, Granulocyte-Macrophage Colony-Stimulating Factor, CHO Cells, Protein Structure, Tertiary, Capsid Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.